Caladrius Biosciences to Present at Upcoming July Conferences
July 07 2016 - 7:30AM
Caladrius Biosciences, Inc. (NASDAQ:CLBS) (“Caladrius” or the
“Company”), a cell therapy company combining an industry-leading
development and manufacturing services provider (PCT) with a select
therapeutic development pipeline, announces today that the
Company’s leadership will present at the following upcoming July
conferences:
Business of Regenerative Medicine: How to Build a
Company
- Date and Time: Monday, July 11, 2016,
2:00 PM ET
- Website:
http://hsci.harvard.edu/event/brm_2016
- Venue: Harvard Business School,
Cambridge, Massachusetts
- Topic: Building the Future: Advanced
Therapies & Scalability
- Presenter: Robert A. Preti, PhD, Senior
Vice President, Manufacturing and Technical Operations and Chief
Technology Officer of Caladrius; President, PCT
CIRM Bridges Meeting
- Date and Time: Monday, July 18, 2016,
4:30 PM PT
- Venue: Claremont Club & Spa,
Berkeley, California
- Topic: Succeeding for the Patient:
Meeting Manufacturing Demands of Advanced Therapies
- Presenter: Robert A. Preti, PhD, Senior
Vice President, Manufacturing and Technical Operations and Chief
Technology Officer of Caladrius; President, PCT
Regenerative Medicine Crossroad
- Date and Time: Thursday, July 28, 2016,
1:50 PM JST
- Website:
https://firm.or.jp/rmit/archives/162
- Venue: Nihonbashi Life Science Building,
Tokyo, Japan
- Topic: Autologous CD34 Cell Therapy for
Treatment of Critical Limb Ischemia Under PMDA Agreement
- Presenter: Douglas W. Losordo, MD, Senior
Vice President Clinical, Medical and Regulatory Affairs and Chief
Medical Officer of Caladrius
About Caladrius Biosciences
Caladrius Biosciences, Inc., through its subsidiary, PCT, is a
leading development and manufacturing partner to the cell therapy
industry. PCT works with its clients to overcome the
fundamental challenges of cell therapy manufacturing by providing a
wide range of innovative services including product and process
development, GMP manufacturing, engineering and automation, cell
and tissue processing, logistics, storage and distribution, as well
as expert consulting and regulatory support. PCT and Hitachi
Chemical Co., Ltd. have entered into a strategic global
collaboration to accelerate the creation of a global commercial
cell therapy development and manufacturing enterprise with deep
engineering expertise. Around the core expertise of PCT,
Caladrius strategically develops select product candidates, which
currently includes an innovative therapy for type 1 diabetes based
on a proprietary platform technology for immunomodulation. For more
information, visit www.caladrius.com.
Forward Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Forward-looking statements reflect management’s current
expectations, as of the date of this press release, and involve
certain risks and uncertainties. All statements other than
statements of historical fact contained in this press release are
forward-looking statements. The Company’s actual results could
differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause
future results to materially differ from the recent results or
those projected in forward-looking statements include the “Risk
Factors” described in the Company’s Annual Report on Form 10-K
filed with the Securities and Exchange Commission (“SEC”) on March
15, 2016, and in the Company’s other periodic filings with the SEC.
The Company’s further development is highly dependent on, among
other things, future medical and research developments and market
acceptance, which are outside of its control.
CONTACTS:
Investors:
LHA
Anne Marie Fields
Senior Vice President
Phone: +1-212-838-3777
Email: afields@lhai.com
Media:
Caladrius Biosciences, Inc.
Eric Powers
Director, Communications and Marketing
Phone: +1-212-584-4173
Email: epowers@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024